Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome

Eken, Meryem; Ersoy, Gülçı̇n Şahin; Abide, Çiğdem Yayla; Sanverdi, Ilhan; Devranoğlu, Belgin; Kutlu, Tayfun; Çevik, Özge

doi:10.1080/01443615.2019.1581754

Cited by 21 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten of the eleven studies stratifying PCOS group according to BMI, revealed significantly higher circulating CRP in obese/overweight versus non-obese PCOS women, while one study showed no difference [96]. On the other hand, eight studies comparing between BMI strata in the control group reported higher CRP levels in the higher BMI group [51,59,78,87,98,100,115,122], while two studies revealed no difference [55,96]. Comparison between different BMI strata between PCOS women and controls is provided in the meta-analysis section below.…”

Section: Systematic Review 221 Crp Resultsmentioning

confidence: 97%

“…To further investigate the effect of obesity as a main confounder on inflammatory status, we separately looked at eleven studies that stratified their participants according to BMI [51,55,59,66,78,87,96,98,100,115,122] and two studies that included only obese participants only [45,110] (Table 1). Ten of the eleven studies stratifying PCOS group according to BMI, revealed significantly higher circulating CRP in obese/overweight versus non-obese PCOS women, while one study showed no difference [96].…”

Section: Systematic Review 221 Crp Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

Aboeldalyl

James

Seyam

et al. 2021

IJMS

View full text Add to dashboard Cite

Although the current literature associates polycystic ovarian syndrome (PCOS) with chronic inflammation, the evidence for this link remains inconclusive and its causal nature remains unclear. The purpose of this systematic review was to assess the inflammatory status in PCOS women and to determine whether it is related to PCOS or to its associated adiposity. We searched electronic databases including PUBMED, EMBASE and MEDLINE, SCOPUS, DynaMed plus, TRIP, ScienceDirect and Cochrane Library, for studies investigating C-reactive protein (CRP) and other inflammatory makers in PCOS women versus healthy controls. Quality and risk of bias for selected studies were assessed using the modified Newcastle–Ottawa scale. CRP data were extracted and pooled using RevMan for calculation of the standardized mean difference (SMD) and 95% confidence interval (CI). Eighty-five eligible studies were included in the systematic review, of which 63 were included in the meta-analysis. Pooled analysis of the 63 studies revealed significantly higher circulating CRP in PCOS women (n = 4086) versus controls (n = 3120) (SMD 1.26, 95%CI, 0.99, 1.53). Sensitivity meta-analysis of 35 high quality studies including non-obese women showed significantly higher circulating CRP in PCOS women versus controls (SMD 1.80, 95%CI, 1.36, 2.25). In conclusion, circulating CRP is moderately elevated in PCOS women independent of obesity, which is indicative of low-grade chronic inflammation.

show abstract

Section: Systematic Review 221 Crp Resultsmentioning

confidence: 97%

Section: Systematic Review 221 Crp Resultsmentioning

confidence: 99%

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

Aboeldalyl

James

Seyam

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…BMI of the non-obese participants ranged from 21.6 to 25.6 kg/m 2 , and BMI of the obese participants ranged from 31.7 to 34.3 kg/m 2 , which is consistent with the inclusion of women with strictly Class 1 (30 to <35 kg/m 2 ) obesity. Studies were conducted across a broad array of countries and included diverse ethnic populations from North America [ 36 , 37 ], South America [ 38 ], Asia [ 39 , 40 , 41 ], and Africa [ 42 , 43 ]. Participants ranged in age from 23.8 to 46.2 years, with the mean age across studies being approximately 29 years.…”

Section: Resultsmentioning

confidence: 99%

Impact of Obesity on Anti-Mullerian Hormone (AMH) Levels in Women of Reproductive Age

Oldfield

Kazemi

Lujan

2021

JCM

View full text Add to dashboard Cite

Obesity negatively impacts reproductive health, including ovarian function. Obesity has been posited to alter Anti-Müllerian hormone (AMH) production. Understanding biological factors that could impact AMH levels is necessary given the increasing use of AMH for predicting reproductive health outcomes in response to controlled ovarian stimulation, diagnosing ovulatory disorders, onset of menopause, and natural conception. In this narrative review, we evaluated the impact of obesity on AMH levels in healthy, regularly cycling reproductive-age women (18–48 years). Thirteen studies (n = 1214 women; (811, non-obese (body mass index; BMI < 30 kg/m2); 403, obese (BMI > 30 kg/m2))) were included, of which five reported decreased AMH levels with obesity, whereas eight showed comparable AMH levels between groups. Inclusion of women with higher obesity classes (Class 3 versus Class 1) may have been a factor in studies reporting lower AMH levels. Together, studies reporting AMH levels in otherwise healthy women remain limited by small sample sizes, cross-sectional designs, and lack of representation across the entire adiposity spectrum. Ultimately, the degree to which obesity may negatively impact AMH levels, and possibly ovarian reserve, in otherwise healthy women with regular menstrual cycles should be deemed uncertain at this time. This conclusion is prudent considering that the biological basis for an impact of obesity on AMH production is unknown.

show abstract

“…Adipose tissue is recognized as a highly active metabolic organ that is the primary storage site for excess energy, but it also serves as an endocrine organ, secreting a number of biologically active compounds, known as adipocytokines or adipokines, involved in the modulation of metabolic homeostasis . Neuregulin 4 (Nrg4) is one of these adipokines and is related to obesity, dyslipidaemia, insulin resistance (IR), inflammation, and oxidative stress (OS) in mouse models and in humans …”

Section: Introductionmentioning

confidence: 99%

A systematic review of the association of neuregulin 4, a brown fat–enriched secreted factor, with obesity and related metabolic disturbances

et al. 2019

View full text Add to dashboard Cite

Neuregulin 4 (Nrg4), a novel brown fat-enriched hormone, plays a key role in the modulation of glucose and lipid metabolism and energy balance. Recent data have demonstrated that the expression of Nrg4 is substantially down-regulated in mouse and human obesity, making its regulatory aspect intriguing. Because of the close relationship between Nrg4, obesity, and associated metabolic diseases, this systematic review aimed to assess the association of Nrg4 with obesity and related metabolic disturbances, emphasizing its possible mechanisms of action in these disorders. We searched PubMed/Medline, ScienceDirect, Scopus, EMBASE, ProQuest, and Google Scholar up until June 2019. The evidence reviewed here indicates that Nrg4 may contribute to the prevention of obesity and related metabolic complications by elevating brown adipose tissue activity, increasing the expression of thermogenic markers, decreasing the expression of lipogenic/ adipogenic genes, exacerbating white adipose tissue browning, increasing the number of brite/beige adipocytes, promoting hepatic fat oxidation and ketogenesis, inducing neurite outgrowth, enhancing blood vessels in adipose tissue, increasing the circulatory levels of healthy adipokines, and improving glucose homeostasis.Thus, Nrg4 appears to be a novel therapeutic strategy for the treatment of obesity and associated metabolic complications. However, prospective cohort studies are warranted to confirm these outcomes.

show abstract

Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome

Cited by 21 publications

References 32 publications

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis

Impact of Obesity on Anti-Mullerian Hormone (AMH) Levels in Women of Reproductive Age

A systematic review of the association of neuregulin 4, a brown fat–enriched secreted factor, with obesity and related metabolic disturbances

Contact Info

Product

Resources

About